Mark S. Shaefer

机构：Triangle, Windsor Dermatology, Jiangsu Hengrui Medicine (China) · ORCID：0000-0002-0545-7304

发表论文 86 篇 · 总被引 3647 次 · h-index 28

代表论文

• Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study (2020 · The Lancet · 被引 375)
• Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks (2020 · AIDS and Behavior · 被引 86)
• Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M) (2021 · Patient · 被引 80)
• HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA® observational database: a cohort study (2019 · AIDS Research and Therapy · 被引 63)
• HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects (2017 · BMC Infectious Diseases · 被引 46)
• Abacavir Use and Risk for Myocardial Infarction and Cardiovascular Events: Pooled Analysis of Data From Clinical Trials (2018 · Open Forum Infectious Diseases · 被引 42)